Advanced colorectal carcinoma: Redefining the role of oral ftorafur

Anti-Cancer Drugs

Volumn 7, Issue 6, 1996, Pages 649-654

  Ron, Ilan G ^a   Lotan, Amir ^a   Inbar, Moshe J ^a   Chaitchik, Samario ^a  

^a TEL AVIV UNIVERSITY   (Israel)

Author keywords

Advanced colorectal carcinoma; Anti tumor; Cost effective; Oral ftorafur

Indexed keywords

FLUOROURACIL; FOLINIC ACID; TEGAFUR;

ADULT; ADVANCED CANCER; AGED; ARTICLE; BLOOD TOXICITY; CLINICAL TRIAL; COLORECTAL CARCINOMA; COST EFFECTIVENESS ANALYSIS; DIARRHEA; FEMALE; HOME CARE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; MALE; NAUSEA; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; PRURITUS; VOMITING;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; ANTIMETABOLITES, ANTINEOPLASTIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COLORECTAL NEOPLASMS; FEMALE; FLUOROURACIL; HOME NURSING; HUMANS; KARNOFSKY PERFORMANCE STATUS; LEUCOVORIN; MALE; MIDDLE AGED; QUALITY OF LIFE; TEGAFUR;

EID: 0029973610     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001813-199608000-00005     Document Type: Article

References (17)

1. Andersen E, Pedersen H, Oral ftorafur versus intravenous 5-fluorouracil. A comparative study in patients with colorectal cancer. Acta Oncol 1987; 26: 433-6.
2. Handschumacher RE, Cheng YC. Purine and pyramidine antimetabolites. In: Holland JF, Frie E III, eds. Cancer medicine. Philadelphia: Lea and Febiger, 1993: 712-28.
3. Petrelli NJ, Mittelman A. An analysis of chemotherapy for colorectal carcinoma. J Surg Oncol 1984; 25: 201-6.
4. Seifert P, Baker LH, Reed ML, Vaitkevicius VK. Comparison of continuously infused 5-fluorouracil with bolus injection in treatment of patients with colorectal adenocarcinoma. Cancer 1975; 36: 123-8.
5. Chu E, Takimoto CH, Antimetabolites. In: DeVita VT Jr, Hellman S, Rosenberg SA, eds. Cancer: principles and practice of oncology. Philadelphia: JH Lippincott 1993: 362-5.
6. Erlichman C, Fine S, Wong A, Elhakin T. A randomized trial of fluorouracil and folinic acid in patients with metastatic colorectal carcinoma. J Clin Oncol 1988; 6: 469-75.
7. Doroshow JH, Multhauf P, Leong L, et al. Prospective randomized comparison of fluorouracil versus fluorouracil and high-dose continuous infusion Leucovorin calcium for treatment of advanced measurable colorectal cancer in patients previously unexposed to chemotherapy. J Clin Oncol 1990; 8: 491-501.
8. Benvenuto JA, Lu K, Hall SW, Benjamin RS, Ti Li Loo. Disposition and metabolism of 1-(tetrahydro-2-furanyl)-5-fluorouracil (ftorafur) in humans. Cancer Res 1978; 38: 3867-70.
9. Van Putten LM, Lelieveld P, Pantarotto C, Salmona M, Spreafico F. Ftorafur: a self limiting source of 5-fluorouracil? Cancer Chemother Pharmacol 1979; 3: 61-6.
10. Friedman MA, Ignoffo RI. A review of the United States clinical experience of the fluoropyramidine, ftorafur (NSC-148958). Cancer Treat Rev 1980; 7: 205-13.
11. Buroker T, Miller A, Baker L, McKenzie M, Samson M, Vaitkevicious VK. Phase II clinical trial of ftorafur in 5-fluorouracil refractory colo-rectal cancer. Cancer Treat Rep 1977; 61: 1579-80.
12. Schutt AJ, Hahn RH, Moertel CG, O'Connell MJ, Rubin J, Creagan ET. Phase II study of ftorafur in previously untreated and treated patients with advanced colorectal cancer. Cancer Treat Rep 1983; 67: 505-6.
13. Palmeri S, Gebbia A, Russo A, Armata MG, Gebbia N, Rausa L. Oral tegafur in the treatment of gastrointestinal tract cancers: a phase II study. Br J Cancer 1990; 61: 475-8.
14. Ansfield FJ, Kallas GJ, Singson JP. Phase I II studies of oral tegafur (Ftorafur). J Clin Oncol 1983; 1: 107-10.
15. Blokhina NG, Vozny EK, Garin AM. Results of treatment of malignant tumors with ftorafur. Cancer 1972; 30: 390-92.
16. Bedikian AY, Bodey GP, Valdivieso M, Burgess MA. Phase I evaluation of oral tegafur. Cancer Treat Rep 1983; 67: 81-4.
17. WHO Handbook for Reporting Results of Cancer Treatment. Offset Publication 48. WHO: Geneva 1979; 22.